secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nabriva Therapeutics plc (—)
CIK:        0001641640
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002268
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 1.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nabriva Therapeutics adopts Cash Preservation Plan to wind down operations, terminates most employees
--------------------------------------------------------------------------------

- Board approved plan on Jan 4, 2023 to preserve cash for an orderly wind down; all employees not needed for wind-down terminated.
- Repaid $4.5M to Hercules Capital under Loan Agreement, terminating the facility and releasing all security interests.
- Estimates ~$6.0M in severance and termination costs in Q1 2023; workforce reduction substantially complete by end of Q1.
- Terminated Amplity Health sales force; will transition SIVEXTRO promotion back to Merck & Co. over coming months.
- Company exploring sale of assets including Lefamulin and IV Fosfomycin; may seek shareholder approval for liquidation/dissolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923002268/0001104659-23-002268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923002268/tm232720d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer